BACKGROUND: Catheter-related venous thrombosis is one of the most frequent complications of central venous catheters (CVCs). This complication occurs in 4- 40% of patients with hematologic malignancies receivingconventional chemotherapy after placement of CVCs. METHODS: The objective of this prospective study was to assess whether a silver-coated CVC poses an additional risk in the development of catheter-related thrombosis in hematologic-oncologic patients. Patients were randomized to receive either silver-coated polyurethane catheters (BactiGuard; Metacot, Stockholm, Sweden) or uncoated standard polyurethane catheters (Cavatheter, Fresenius AG, Bad Homburg, Germany) for central venous access. Silver-coated catheters (n = 120) and standard catheters (n = 113) were inserted into the jugular vein in 233 consecutive patients. Variables that may be significant for the development of thrombosis were comparable in the two groups. After removal of the CVC, the patency of both jugularian veins internal as well as external was assessed with real-time ultrasound (Sonolayer-SAL-35A; Toshiba, Tokyo, Japan). RESULTS: Four of 233 patients (1.5%) were found to have venous thrombosis. Incomplete occlusion of the internal jugular vein occurred in 2 patients (0.75%, parietal thrombosis), and complete thrombosis, although clinically silent, was found in 2 patients (0.75%). There was no difference between patients with silver-coated and uncoated CVCs. CONCLUSIONS: The authors concluded that this novel silver-coated CVC does not cause a higher rate of central venous thrombosis compared with standard CVCs. The low overall incidence of central venous thrombosis might be attributed to the routine application of low-dose heparin in our patients during chemotherapeutic treatment. Copyright 2002 American Cancer Society.
RCT Entities:
BACKGROUND: Catheter-related venous thrombosis is one of the most frequent complications of central venous catheters (CVCs). This complication occurs in 4- 40% of patients with hematologic malignancies receiving conventional chemotherapy after placement of CVCs. METHODS: The objective of this prospective study was to assess whether a silver-coated CVC poses an additional risk in the development of catheter-related thrombosis in hematologic-oncologic patients. Patients were randomized to receive either silver-coated polyurethane catheters (BactiGuard; Metacot, Stockholm, Sweden) or uncoated standard polyurethane catheters (Cavatheter, Fresenius AG, Bad Homburg, Germany) for central venous access. Silver-coated catheters (n = 120) and standard catheters (n = 113) were inserted into the jugular vein in 233 consecutive patients. Variables that may be significant for the development of thrombosis were comparable in the two groups. After removal of the CVC, the patency of both jugularian veins internal as well as external was assessed with real-time ultrasound (Sonolayer-SAL-35A; Toshiba, Tokyo, Japan). RESULTS: Four of 233 patients (1.5%) were found to have venous thrombosis. Incomplete occlusion of the internal jugular vein occurred in 2 patients (0.75%, parietal thrombosis), and complete thrombosis, although clinically silent, was found in 2 patients (0.75%). There was no difference between patients with silver-coated and uncoated CVCs. CONCLUSIONS: The authors concluded that this novel silver-coated CVC does not cause a higher rate of central venous thrombosis compared with standard CVCs. The low overall incidence of central venous thrombosis might be attributed to the routine application of low-dose heparin in our patients during chemotherapeutic treatment. Copyright 2002 American Cancer Society.
Authors: Torben Ostendorf; Andrea Meinhold; Christoph Harter; Hans Salwender; Gerlinde Egerer; Heinrich K Geiss; Antony D Ho; Hartmut Goldschmidt Journal: Support Care Cancer Date: 2005-04-16 Impact factor: 3.603
Authors: Nuriye Yildirim Ozdemir; Hüseyin Abali; Berna Oksüzoğlu; Burçin Budakoğlu; Ilkay Akmangit; Nurullah Zengin Journal: Support Care Cancer Date: 2008-09-02 Impact factor: 3.603
Authors: Luigi Cavanna; Maria Rosa Cordani; Claudia Biasini; Camilla Di Nunzio; Michela Monfredo; Elisa Stroppa; Monica Muroni; Massimo Ambroggi; Lara Muroni; Roberto Di Cicilia; Gabriele Cremona; Elisabetta Nobili; Elena Zaffignani; Giuseppe Civardi Journal: World J Oncol Date: 2011-10-28
Authors: Nai Ming Lai; Nathorn Chaiyakunapruk; Nai An Lai; Elizabeth O'Riordan; Wilson Shu Cheng Pau; Sanjay Saint Journal: Cochrane Database Syst Rev Date: 2016-03-16
Authors: Gunilla Björling; Dorota Johansson; Linda Bergström; Anton Strekalovsky; Javier Sanchez; Claes Frostell; Sigridur Kalman Journal: J Biomed Mater Res B Appl Biomater Date: 2017-11-06 Impact factor: 3.368